Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adults.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy（2023）

引用 0|浏览0

暂无评分

摘要

gov, NCT04896541.

查看译文

关键词

SARS-CoV-2,COVID-19,Monoclonal antibody,Phase 1,Safety,Pharmacokinetics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要